nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxepin—CYP2C19—Methimazole—Graves' disease	0.183	0.25	CbGbCtD
Doxepin—CYP1A2—Methimazole—Graves' disease	0.169	0.231	CbGbCtD
Doxepin—CYP2C9—Methimazole—Graves' disease	0.152	0.208	CbGbCtD
Doxepin—CYP2D6—Methimazole—Graves' disease	0.139	0.19	CbGbCtD
Doxepin—CYP3A4—Methimazole—Graves' disease	0.0886	0.121	CbGbCtD
Doxepin—Drug fever—Methimazole—Graves' disease	0.0248	0.104	CcSEcCtD
Doxepin—Epigastric distress—Methimazole—Graves' disease	0.0214	0.0896	CcSEcCtD
Doxepin—Drug fever—Propylthiouracil—Graves' disease	0.0211	0.0885	CcSEcCtD
Doxepin—Epigastric distress—Propylthiouracil—Graves' disease	0.0182	0.0762	CcSEcCtD
Doxepin—Ageusia—Methimazole—Graves' disease	0.0102	0.0429	CcSEcCtD
Doxepin—Ageusia—Propylthiouracil—Graves' disease	0.0087	0.0365	CcSEcCtD
Doxepin—Drowsiness—Methimazole—Graves' disease	0.00463	0.0194	CcSEcCtD
Doxepin—Neuropathy peripheral—Methimazole—Graves' disease	0.00454	0.019	CcSEcCtD
Doxepin—Jaundice—Methimazole—Graves' disease	0.00452	0.0189	CcSEcCtD
Doxepin—Agranulocytosis—Methimazole—Graves' disease	0.00432	0.0181	CcSEcCtD
Doxepin—Hepatitis—Methimazole—Graves' disease	0.00416	0.0174	CcSEcCtD
Doxepin—Drowsiness—Propylthiouracil—Graves' disease	0.00394	0.0165	CcSEcCtD
Doxepin—Neuropathy peripheral—Propylthiouracil—Graves' disease	0.00386	0.0162	CcSEcCtD
Doxepin—Jaundice—Propylthiouracil—Graves' disease	0.00384	0.0161	CcSEcCtD
Doxepin—Agranulocytosis—Propylthiouracil—Graves' disease	0.00368	0.0154	CcSEcCtD
Doxepin—Alopecia—Methimazole—Graves' disease	0.00368	0.0154	CcSEcCtD
Doxepin—Hepatitis—Propylthiouracil—Graves' disease	0.00354	0.0148	CcSEcCtD
Doxepin—Vertigo—Methimazole—Graves' disease	0.00325	0.0136	CcSEcCtD
Doxepin—Leukopenia—Methimazole—Graves' disease	0.00324	0.0136	CcSEcCtD
Doxepin—Alopecia—Propylthiouracil—Graves' disease	0.00313	0.0131	CcSEcCtD
Doxepin—Myalgia—Methimazole—Graves' disease	0.00308	0.0129	CcSEcCtD
Doxepin—Arthralgia—Methimazole—Graves' disease	0.00308	0.0129	CcSEcCtD
Doxepin—Dysgeusia—Propylthiouracil—Graves' disease	0.00302	0.0126	CcSEcCtD
Doxepin—Oedema—Methimazole—Graves' disease	0.00296	0.0124	CcSEcCtD
Doxepin—Thrombocytopenia—Methimazole—Graves' disease	0.00289	0.0121	CcSEcCtD
Doxepin—Vertigo—Propylthiouracil—Graves' disease	0.00277	0.0116	CcSEcCtD
Doxepin—Leukopenia—Propylthiouracil—Graves' disease	0.00276	0.0116	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Methimazole—Graves' disease	0.00269	0.0113	CcSEcCtD
Doxepin—Paraesthesia—Methimazole—Graves' disease	0.00265	0.0111	CcSEcCtD
Doxepin—Somnolence—Methimazole—Graves' disease	0.00263	0.011	CcSEcCtD
Doxepin—Arthralgia—Propylthiouracil—Graves' disease	0.00262	0.011	CcSEcCtD
Doxepin—Myalgia—Propylthiouracil—Graves' disease	0.00262	0.011	CcSEcCtD
Doxepin—Dyspepsia—Methimazole—Graves' disease	0.0026	0.0109	CcSEcCtD
Doxepin—Oedema—Propylthiouracil—Graves' disease	0.00251	0.0105	CcSEcCtD
Doxepin—Thrombocytopenia—Propylthiouracil—Graves' disease	0.00246	0.0103	CcSEcCtD
Doxepin—Urticaria—Methimazole—Graves' disease	0.00235	0.00984	CcSEcCtD
Doxepin—Body temperature increased—Methimazole—Graves' disease	0.00234	0.0098	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.00229	0.0096	CcSEcCtD
Doxepin—Paraesthesia—Propylthiouracil—Graves' disease	0.00226	0.00946	CcSEcCtD
Doxepin—Somnolence—Propylthiouracil—Graves' disease	0.00223	0.00937	CcSEcCtD
Doxepin—Dyspepsia—Propylthiouracil—Graves' disease	0.00221	0.00927	CcSEcCtD
Doxepin—Pruritus—Methimazole—Graves' disease	0.00209	0.00877	CcSEcCtD
Doxepin—Urticaria—Propylthiouracil—Graves' disease	0.002	0.00837	CcSEcCtD
Doxepin—Body temperature increased—Propylthiouracil—Graves' disease	0.00199	0.00833	CcSEcCtD
Doxepin—Vomiting—Methimazole—Graves' disease	0.00188	0.00788	CcSEcCtD
Doxepin—Rash—Methimazole—Graves' disease	0.00186	0.00781	CcSEcCtD
Doxepin—Dermatitis—Methimazole—Graves' disease	0.00186	0.00781	CcSEcCtD
Doxepin—Headache—Methimazole—Graves' disease	0.00185	0.00776	CcSEcCtD
Doxepin—Pruritus—Propylthiouracil—Graves' disease	0.00178	0.00745	CcSEcCtD
Doxepin—Nausea—Methimazole—Graves' disease	0.00176	0.00736	CcSEcCtD
Doxepin—Vomiting—Propylthiouracil—Graves' disease	0.0016	0.0067	CcSEcCtD
Doxepin—Rash—Propylthiouracil—Graves' disease	0.00158	0.00664	CcSEcCtD
Doxepin—Dermatitis—Propylthiouracil—Graves' disease	0.00158	0.00664	CcSEcCtD
Doxepin—Headache—Propylthiouracil—Graves' disease	0.00157	0.0066	CcSEcCtD
Doxepin—Nausea—Propylthiouracil—Graves' disease	0.00149	0.00626	CcSEcCtD
Doxepin—HRH4—GPCR downstream signaling—CXCL10—Graves' disease	6.02e-05	0.00209	CbGpPWpGaD
Doxepin—ADRA2C—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	6.02e-05	0.00209	CbGpPWpGaD
Doxepin—CHRM4—GPCR ligand binding—CXCL10—Graves' disease	5.98e-05	0.00208	CbGpPWpGaD
Doxepin—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	5.96e-05	0.00207	CbGpPWpGaD
Doxepin—DRD2—Circadian rythm related genes—FAS—Graves' disease	5.93e-05	0.00206	CbGpPWpGaD
Doxepin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	5.87e-05	0.00204	CbGpPWpGaD
Doxepin—CHRM1—Circadian rythm related genes—FAS—Graves' disease	5.8e-05	0.00202	CbGpPWpGaD
Doxepin—HTR2B—GPCR ligand binding—CXCL10—Graves' disease	5.79e-05	0.00201	CbGpPWpGaD
Doxepin—CHRM5—GPCR ligand binding—CXCL10—Graves' disease	5.73e-05	0.00199	CbGpPWpGaD
Doxepin—ADRA2A—GPCR ligand binding—TSHR—Graves' disease	5.71e-05	0.00198	CbGpPWpGaD
Doxepin—KCNH2—SIDS Susceptibility Pathways—TNF—Graves' disease	5.6e-05	0.00195	CbGpPWpGaD
Doxepin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	5.58e-05	0.00194	CbGpPWpGaD
Doxepin—HTR6—GPCR downstream signaling—TSHR—Graves' disease	5.54e-05	0.00193	CbGpPWpGaD
Doxepin—HRH4—Signaling by GPCR—CXCL10—Graves' disease	5.47e-05	0.0019	CbGpPWpGaD
Doxepin—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	5.41e-05	0.00188	CbGpPWpGaD
Doxepin—ADRA1D—GPCR ligand binding—CXCL10—Graves' disease	5.38e-05	0.00187	CbGpPWpGaD
Doxepin—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	5.32e-05	0.00185	CbGpPWpGaD
Doxepin—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	5.31e-05	0.00185	CbGpPWpGaD
Doxepin—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	5.3e-05	0.00184	CbGpPWpGaD
Doxepin—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	5.28e-05	0.00184	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism of lipids and lipoproteins—GC—Graves' disease	5.24e-05	0.00182	CbGpPWpGaD
Doxepin—CHRM4—GPCR downstream signaling—TSHR—Graves' disease	5.23e-05	0.00182	CbGpPWpGaD
Doxepin—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	5.23e-05	0.00182	CbGpPWpGaD
Doxepin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	5.21e-05	0.00181	CbGpPWpGaD
Doxepin—ABCB1—Allograft Rejection—IFNG—Graves' disease	5.08e-05	0.00177	CbGpPWpGaD
Doxepin—HTR2B—GPCR downstream signaling—TSHR—Graves' disease	5.06e-05	0.00176	CbGpPWpGaD
Doxepin—SLC6A4—SIDS Susceptibility Pathways—TNF—Graves' disease	5.04e-05	0.00175	CbGpPWpGaD
Doxepin—HTR6—Signaling by GPCR—TSHR—Graves' disease	5.03e-05	0.00175	CbGpPWpGaD
Doxepin—CHRM5—GPCR downstream signaling—TSHR—Graves' disease	5.01e-05	0.00174	CbGpPWpGaD
Doxepin—HRH4—Signaling Pathways—TSHR—Graves' disease	5e-05	0.00174	CbGpPWpGaD
Doxepin—ADRA2A—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	4.89e-05	0.0017	CbGpPWpGaD
Doxepin—ADRA2B—GPCR ligand binding—CXCL10—Graves' disease	4.86e-05	0.00169	CbGpPWpGaD
Doxepin—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	4.84e-05	0.00168	CbGpPWpGaD
Doxepin—HTR1A—SIDS Susceptibility Pathways—IL1B—Graves' disease	4.84e-05	0.00168	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism of lipids and lipoproteins—GC—Graves' disease	4.78e-05	0.00166	CbGpPWpGaD
Doxepin—CHRM4—Signaling by GPCR—TSHR—Graves' disease	4.75e-05	0.00165	CbGpPWpGaD
Doxepin—ADRA1D—GPCR downstream signaling—TSHR—Graves' disease	4.71e-05	0.00164	CbGpPWpGaD
Doxepin—HTR1A—GPCR ligand binding—CXCL10—Graves' disease	4.69e-05	0.00163	CbGpPWpGaD
Doxepin—HRH2—GPCR downstream signaling—CXCL10—Graves' disease	4.67e-05	0.00162	CbGpPWpGaD
Doxepin—HTR2C—GPCR ligand binding—CXCL10—Graves' disease	4.67e-05	0.00162	CbGpPWpGaD
Doxepin—HRH4—GPCR downstream signaling—IL2RA—Graves' disease	4.6e-05	0.0016	CbGpPWpGaD
Doxepin—HTR2B—Signaling by GPCR—TSHR—Graves' disease	4.6e-05	0.0016	CbGpPWpGaD
Doxepin—CHRM5—Signaling by GPCR—TSHR—Graves' disease	4.55e-05	0.00158	CbGpPWpGaD
Doxepin—ADRA2C—GPCR ligand binding—CXCL10—Graves' disease	4.54e-05	0.00158	CbGpPWpGaD
Doxepin—ABCB1—Allograft Rejection—IL1B—Graves' disease	4.53e-05	0.00158	CbGpPWpGaD
Doxepin—ABCB1—Transmembrane transport of small molecules—GABRA3—Graves' disease	4.52e-05	0.00157	CbGpPWpGaD
Doxepin—ADRA1B—GPCR ligand binding—CXCL10—Graves' disease	4.47e-05	0.00155	CbGpPWpGaD
Doxepin—ADRA1D—Signaling by GPCR—TSHR—Graves' disease	4.28e-05	0.00149	CbGpPWpGaD
Doxepin—ADRA2B—GPCR downstream signaling—TSHR—Graves' disease	4.25e-05	0.00148	CbGpPWpGaD
Doxepin—HRH2—Signaling by GPCR—CXCL10—Graves' disease	4.24e-05	0.00148	CbGpPWpGaD
Doxepin—HRH4—Signaling by GPCR—IL2RA—Graves' disease	4.18e-05	0.00145	CbGpPWpGaD
Doxepin—HTR2A—SIDS Susceptibility Pathways—IL1B—Graves' disease	4.18e-05	0.00145	CbGpPWpGaD
Doxepin—DRD2—GPCR ligand binding—CXCL10—Graves' disease	4.12e-05	0.00143	CbGpPWpGaD
Doxepin—HTR1A—GPCR downstream signaling—TSHR—Graves' disease	4.1e-05	0.00143	CbGpPWpGaD
Doxepin—CHRM2—SIDS Susceptibility Pathways—IL1B—Graves' disease	4.1e-05	0.00143	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism of lipids and lipoproteins—GC—Graves' disease	4.08e-05	0.00142	CbGpPWpGaD
Doxepin—HTR2C—GPCR downstream signaling—TSHR—Graves' disease	4.08e-05	0.00142	CbGpPWpGaD
Doxepin—ADRA2C—Metabolism—GC—Graves' disease	4.06e-05	0.00141	CbGpPWpGaD
Doxepin—HTR2A—GPCR ligand binding—CXCL10—Graves' disease	4.05e-05	0.00141	CbGpPWpGaD
Doxepin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	4.05e-05	0.00141	CbGpPWpGaD
Doxepin—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Graves' disease	4.05e-05	0.00141	CbGpPWpGaD
Doxepin—HRH1—GPCR ligand binding—CXCL10—Graves' disease	4.05e-05	0.00141	CbGpPWpGaD
Doxepin—CHRM1—GPCR ligand binding—CXCL10—Graves' disease	4.03e-05	0.0014	CbGpPWpGaD
Doxepin—CHRM3—GPCR ligand binding—CXCL10—Graves' disease	4.02e-05	0.0014	CbGpPWpGaD
Doxepin—CHRM2—GPCR ligand binding—CXCL10—Graves' disease	3.98e-05	0.00138	CbGpPWpGaD
Doxepin—ADRA2C—GPCR downstream signaling—TSHR—Graves' disease	3.97e-05	0.00138	CbGpPWpGaD
Doxepin—ADRA1A—GPCR ligand binding—CXCL10—Graves' disease	3.97e-05	0.00138	CbGpPWpGaD
Doxepin—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	3.96e-05	0.00138	CbGpPWpGaD
Doxepin—ADRA1B—GPCR downstream signaling—TSHR—Graves' disease	3.91e-05	0.00136	CbGpPWpGaD
Doxepin—HRH2—Signaling Pathways—TSHR—Graves' disease	3.88e-05	0.00135	CbGpPWpGaD
Doxepin—ADRA2B—Signaling by GPCR—TSHR—Graves' disease	3.86e-05	0.00134	CbGpPWpGaD
Doxepin—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	3.82e-05	0.00133	CbGpPWpGaD
Doxepin—HTR1A—Signaling by GPCR—TSHR—Graves' disease	3.73e-05	0.0013	CbGpPWpGaD
Doxepin—HTR2C—Signaling by GPCR—TSHR—Graves' disease	3.71e-05	0.00129	CbGpPWpGaD
Doxepin—ADRA2A—GPCR ligand binding—CXCL10—Graves' disease	3.69e-05	0.00128	CbGpPWpGaD
Doxepin—ADRA2C—Signaling by GPCR—TSHR—Graves' disease	3.61e-05	0.00125	CbGpPWpGaD
Doxepin—DRD2—GPCR downstream signaling—TSHR—Graves' disease	3.6e-05	0.00125	CbGpPWpGaD
Doxepin—CHRM3—Metabolism—GC—Graves' disease	3.59e-05	0.00125	CbGpPWpGaD
Doxepin—HTR6—GPCR downstream signaling—CXCL10—Graves' disease	3.58e-05	0.00125	CbGpPWpGaD
Doxepin—HRH2—GPCR downstream signaling—IL2RA—Graves' disease	3.57e-05	0.00124	CbGpPWpGaD
Doxepin—ADRA1B—Signaling by GPCR—TSHR—Graves' disease	3.55e-05	0.00123	CbGpPWpGaD
Doxepin—HTR2A—GPCR downstream signaling—TSHR—Graves' disease	3.55e-05	0.00123	CbGpPWpGaD
Doxepin—HRH1—GPCR downstream signaling—TSHR—Graves' disease	3.54e-05	0.00123	CbGpPWpGaD
Doxepin—CHRM1—GPCR downstream signaling—TSHR—Graves' disease	3.53e-05	0.00123	CbGpPWpGaD
Doxepin—CHRM3—GPCR downstream signaling—TSHR—Graves' disease	3.52e-05	0.00122	CbGpPWpGaD
Doxepin—HTR1A—SIDS Susceptibility Pathways—TNF—Graves' disease	3.51e-05	0.00122	CbGpPWpGaD
Doxepin—CHRM2—GPCR downstream signaling—TSHR—Graves' disease	3.48e-05	0.00121	CbGpPWpGaD
Doxepin—ADRA1A—GPCR downstream signaling—TSHR—Graves' disease	3.47e-05	0.00121	CbGpPWpGaD
Doxepin—CHRM4—GPCR downstream signaling—CXCL10—Graves' disease	3.38e-05	0.00118	CbGpPWpGaD
Doxepin—ADRA2B—Hemostasis—IL2RA—Graves' disease	3.32e-05	0.00116	CbGpPWpGaD
Doxepin—ADRA2A—Metabolism—GC—Graves' disease	3.3e-05	0.00115	CbGpPWpGaD
Doxepin—ABCB1—Allograft Rejection—TNF—Graves' disease	3.29e-05	0.00114	CbGpPWpGaD
Doxepin—DRD2—Signaling by GPCR—TSHR—Graves' disease	3.27e-05	0.00114	CbGpPWpGaD
Doxepin—HTR2B—GPCR downstream signaling—CXCL10—Graves' disease	3.27e-05	0.00114	CbGpPWpGaD
Doxepin—HTR6—Signaling by GPCR—CXCL10—Graves' disease	3.25e-05	0.00113	CbGpPWpGaD
Doxepin—HRH2—Signaling by GPCR—IL2RA—Graves' disease	3.24e-05	0.00113	CbGpPWpGaD
Doxepin—CHRM5—GPCR downstream signaling—CXCL10—Graves' disease	3.24e-05	0.00113	CbGpPWpGaD
Doxepin—HRH4—Signaling Pathways—CXCL10—Graves' disease	3.23e-05	0.00112	CbGpPWpGaD
Doxepin—ADRA2A—GPCR downstream signaling—TSHR—Graves' disease	3.23e-05	0.00112	CbGpPWpGaD
Doxepin—HTR2A—Signaling by GPCR—TSHR—Graves' disease	3.22e-05	0.00112	CbGpPWpGaD
Doxepin—HRH1—Signaling by GPCR—TSHR—Graves' disease	3.21e-05	0.00112	CbGpPWpGaD
Doxepin—CHRM1—Signaling by GPCR—TSHR—Graves' disease	3.2e-05	0.00111	CbGpPWpGaD
Doxepin—CHRM3—Signaling by GPCR—TSHR—Graves' disease	3.19e-05	0.00111	CbGpPWpGaD
Doxepin—CHRM2—Signaling by GPCR—TSHR—Graves' disease	3.16e-05	0.0011	CbGpPWpGaD
Doxepin—ADRA1A—Signaling by GPCR—TSHR—Graves' disease	3.15e-05	0.0011	CbGpPWpGaD
Doxepin—ADRA2C—Hemostasis—IL2RA—Graves' disease	3.1e-05	0.00108	CbGpPWpGaD
Doxepin—ADRA2C—Metabolism—B3GNT2—Graves' disease	3.07e-05	0.00107	CbGpPWpGaD
Doxepin—CHRM4—Signaling by GPCR—CXCL10—Graves' disease	3.07e-05	0.00107	CbGpPWpGaD
Doxepin—ADRA1D—GPCR downstream signaling—CXCL10—Graves' disease	3.04e-05	0.00106	CbGpPWpGaD
Doxepin—HTR2A—SIDS Susceptibility Pathways—TNF—Graves' disease	3.03e-05	0.00105	CbGpPWpGaD
Doxepin—CHRM2—SIDS Susceptibility Pathways—TNF—Graves' disease	2.98e-05	0.00104	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—TSHR—Graves' disease	2.97e-05	0.00103	CbGpPWpGaD
Doxepin—HTR2B—Signaling by GPCR—CXCL10—Graves' disease	2.97e-05	0.00103	CbGpPWpGaD
Doxepin—CHRM5—Signaling by GPCR—CXCL10—Graves' disease	2.94e-05	0.00102	CbGpPWpGaD
Doxepin—ADRA2A—Signaling by GPCR—TSHR—Graves' disease	2.93e-05	0.00102	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—TSHR—Graves' disease	2.81e-05	0.000976	CbGpPWpGaD
Doxepin—ADRA1D—Signaling by GPCR—CXCL10—Graves' disease	2.76e-05	0.000961	CbGpPWpGaD
Doxepin—ADRA2B—GPCR downstream signaling—CXCL10—Graves' disease	2.75e-05	0.000955	CbGpPWpGaD
Doxepin—HTR6—GPCR downstream signaling—IL2RA—Graves' disease	2.74e-05	0.000952	CbGpPWpGaD
Doxepin—CHRM3—Metabolism—B3GNT2—Graves' disease	2.72e-05	0.000946	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—TSHR—Graves' disease	2.71e-05	0.000944	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—TSHR—Graves' disease	2.69e-05	0.000934	CbGpPWpGaD
Doxepin—HTR1A—GPCR downstream signaling—CXCL10—Graves' disease	2.65e-05	0.000922	CbGpPWpGaD
Doxepin—HTR2C—GPCR downstream signaling—CXCL10—Graves' disease	2.64e-05	0.000917	CbGpPWpGaD
Doxepin—CHRM4—GPCR downstream signaling—IL2RA—Graves' disease	2.58e-05	0.000898	CbGpPWpGaD
Doxepin—ADRA2C—GPCR downstream signaling—CXCL10—Graves' disease	2.57e-05	0.000892	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—TSHR—Graves' disease	2.53e-05	0.000878	CbGpPWpGaD
Doxepin—ADRA1B—GPCR downstream signaling—CXCL10—Graves' disease	2.53e-05	0.000878	CbGpPWpGaD
Doxepin—ADRA2A—Hemostasis—IL2RA—Graves' disease	2.52e-05	0.000877	CbGpPWpGaD
Doxepin—HRH2—Signaling Pathways—CXCL10—Graves' disease	2.51e-05	0.000871	CbGpPWpGaD
Doxepin—HTR2B—GPCR downstream signaling—IL2RA—Graves' disease	2.5e-05	0.000869	CbGpPWpGaD
Doxepin—ADRA2A—Metabolism—B3GNT2—Graves' disease	2.5e-05	0.000868	CbGpPWpGaD
Doxepin—ADRA2B—Signaling by GPCR—CXCL10—Graves' disease	2.49e-05	0.000867	CbGpPWpGaD
Doxepin—HTR6—Signaling by GPCR—IL2RA—Graves' disease	2.49e-05	0.000865	CbGpPWpGaD
Doxepin—CHRM5—GPCR downstream signaling—IL2RA—Graves' disease	2.47e-05	0.00086	CbGpPWpGaD
Doxepin—HRH4—Signaling Pathways—IL2RA—Graves' disease	2.47e-05	0.000859	CbGpPWpGaD
Doxepin—HTR1A—Signaling by GPCR—CXCL10—Graves' disease	2.41e-05	0.000837	CbGpPWpGaD
Doxepin—HTR2C—Signaling by GPCR—CXCL10—Graves' disease	2.4e-05	0.000833	CbGpPWpGaD
Doxepin—CHRM4—Signaling by GPCR—IL2RA—Graves' disease	2.35e-05	0.000816	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—GC—Graves' disease	2.33e-05	0.000812	CbGpPWpGaD
Doxepin—ADRA2C—Signaling by GPCR—CXCL10—Graves' disease	2.33e-05	0.00081	CbGpPWpGaD
Doxepin—DRD2—GPCR downstream signaling—CXCL10—Graves' disease	2.33e-05	0.00081	CbGpPWpGaD
Doxepin—ADRA1D—GPCR downstream signaling—IL2RA—Graves' disease	2.33e-05	0.000809	CbGpPWpGaD
Doxepin—ADRA1B—Signaling by GPCR—CXCL10—Graves' disease	2.29e-05	0.000797	CbGpPWpGaD
Doxepin—HTR2A—GPCR downstream signaling—CXCL10—Graves' disease	2.29e-05	0.000797	CbGpPWpGaD
Doxepin—HRH1—GPCR downstream signaling—CXCL10—Graves' disease	2.29e-05	0.000795	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—TSHR—Graves' disease	2.28e-05	0.000793	CbGpPWpGaD
Doxepin—CHRM1—GPCR downstream signaling—CXCL10—Graves' disease	2.28e-05	0.000792	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—GC—Graves' disease	2.28e-05	0.000792	CbGpPWpGaD
Doxepin—CHRM3—GPCR downstream signaling—CXCL10—Graves' disease	2.27e-05	0.00079	CbGpPWpGaD
Doxepin—HTR2B—Signaling by GPCR—IL2RA—Graves' disease	2.27e-05	0.000789	CbGpPWpGaD
Doxepin—CHRM2—GPCR downstream signaling—CXCL10—Graves' disease	2.25e-05	0.000782	CbGpPWpGaD
Doxepin—CHRM5—Signaling by GPCR—IL2RA—Graves' disease	2.25e-05	0.000781	CbGpPWpGaD
Doxepin—ADRA1A—GPCR downstream signaling—CXCL10—Graves' disease	2.24e-05	0.00078	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—TSHR—Graves' disease	2.2e-05	0.000766	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—TSHR—Graves' disease	2.19e-05	0.000762	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—GC—Graves' disease	2.15e-05	0.000747	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—TSHR—Graves' disease	2.13e-05	0.000741	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—GC—Graves' disease	2.13e-05	0.00074	CbGpPWpGaD
Doxepin—DRD2—Signaling by GPCR—CXCL10—Graves' disease	2.11e-05	0.000735	CbGpPWpGaD
Doxepin—ADRA1D—Signaling by GPCR—IL2RA—Graves' disease	2.11e-05	0.000734	CbGpPWpGaD
Doxepin—ADRA2B—GPCR downstream signaling—IL2RA—Graves' disease	2.1e-05	0.00073	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—TSHR—Graves' disease	2.1e-05	0.000729	CbGpPWpGaD
Doxepin—ADRA2A—GPCR downstream signaling—CXCL10—Graves' disease	2.08e-05	0.000725	CbGpPWpGaD
Doxepin—HTR2A—Signaling by GPCR—CXCL10—Graves' disease	2.08e-05	0.000723	CbGpPWpGaD
Doxepin—HRH1—Signaling by GPCR—CXCL10—Graves' disease	2.08e-05	0.000722	CbGpPWpGaD
Doxepin—CHRM1—Signaling by GPCR—CXCL10—Graves' disease	2.07e-05	0.00072	CbGpPWpGaD
Doxepin—CHRM3—Signaling by GPCR—CXCL10—Graves' disease	2.06e-05	0.000717	CbGpPWpGaD
Doxepin—CHRM2—Signaling by GPCR—CXCL10—Graves' disease	2.04e-05	0.00071	CbGpPWpGaD
Doxepin—ADRA1A—Signaling by GPCR—CXCL10—Graves' disease	2.04e-05	0.000708	CbGpPWpGaD
Doxepin—HTR1A—GPCR downstream signaling—IL2RA—Graves' disease	2.03e-05	0.000705	CbGpPWpGaD
Doxepin—HTR2C—GPCR downstream signaling—IL2RA—Graves' disease	2.02e-05	0.000701	CbGpPWpGaD
Doxepin—ADRA2C—GPCR downstream signaling—IL2RA—Graves' disease	1.96e-05	0.000682	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—TSHR—Graves' disease	1.93e-05	0.000672	CbGpPWpGaD
Doxepin—ADRA1B—GPCR downstream signaling—IL2RA—Graves' disease	1.93e-05	0.000671	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—CXCL10—Graves' disease	1.92e-05	0.000668	CbGpPWpGaD
Doxepin—HRH2—Signaling Pathways—IL2RA—Graves' disease	1.92e-05	0.000666	CbGpPWpGaD
Doxepin—ADRA2B—Signaling by GPCR—IL2RA—Graves' disease	1.91e-05	0.000663	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—TSHR—Graves' disease	1.9e-05	0.000661	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—TSHR—Graves' disease	1.9e-05	0.00066	CbGpPWpGaD
Doxepin—ADRA2A—Signaling by GPCR—CXCL10—Graves' disease	1.89e-05	0.000658	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—TSHR—Graves' disease	1.89e-05	0.000658	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—TSHR—Graves' disease	1.89e-05	0.000656	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—TSHR—Graves' disease	1.87e-05	0.000649	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—TSHR—Graves' disease	1.86e-05	0.000648	CbGpPWpGaD
Doxepin—HTR1A—Signaling by GPCR—IL2RA—Graves' disease	1.84e-05	0.00064	CbGpPWpGaD
Doxepin—HTR2C—Signaling by GPCR—IL2RA—Graves' disease	1.83e-05	0.000637	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—GC—Graves' disease	1.82e-05	0.000633	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—CXCL10—Graves' disease	1.81e-05	0.00063	CbGpPWpGaD
Doxepin—ADRA2C—Signaling by GPCR—IL2RA—Graves' disease	1.78e-05	0.000619	CbGpPWpGaD
Doxepin—DRD2—GPCR downstream signaling—IL2RA—Graves' disease	1.78e-05	0.000619	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—B3GNT2—Graves' disease	1.77e-05	0.000615	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—CXCL10—Graves' disease	1.75e-05	0.00061	CbGpPWpGaD
Doxepin—ADRA1B—Signaling by GPCR—IL2RA—Graves' disease	1.75e-05	0.00061	CbGpPWpGaD
Doxepin—HTR2A—GPCR downstream signaling—IL2RA—Graves' disease	1.75e-05	0.000609	CbGpPWpGaD
Doxepin—HRH1—GPCR downstream signaling—IL2RA—Graves' disease	1.75e-05	0.000608	CbGpPWpGaD
Doxepin—CHRM1—GPCR downstream signaling—IL2RA—Graves' disease	1.74e-05	0.000606	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—CXCL10—Graves' disease	1.74e-05	0.000604	CbGpPWpGaD
Doxepin—CHRM3—GPCR downstream signaling—IL2RA—Graves' disease	1.74e-05	0.000604	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—TSHR—Graves' disease	1.73e-05	0.000602	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—B3GNT2—Graves' disease	1.73e-05	0.000601	CbGpPWpGaD
Doxepin—CHRM2—GPCR downstream signaling—IL2RA—Graves' disease	1.72e-05	0.000598	CbGpPWpGaD
Doxepin—ADRA1A—GPCR downstream signaling—IL2RA—Graves' disease	1.71e-05	0.000596	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—CXCL10—Graves' disease	1.63e-05	0.000568	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—B3GNT2—Graves' disease	1.63e-05	0.000566	CbGpPWpGaD
Doxepin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	1.62e-05	0.000564	CbGpPWpGaD
Doxepin—DRD2—Signaling by GPCR—IL2RA—Graves' disease	1.62e-05	0.000562	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—B3GNT2—Graves' disease	1.61e-05	0.000561	CbGpPWpGaD
Doxepin—ADRA2A—GPCR downstream signaling—IL2RA—Graves' disease	1.59e-05	0.000554	CbGpPWpGaD
Doxepin—HTR2A—Signaling by GPCR—IL2RA—Graves' disease	1.59e-05	0.000553	CbGpPWpGaD
Doxepin—HRH1—Signaling by GPCR—IL2RA—Graves' disease	1.59e-05	0.000552	CbGpPWpGaD
Doxepin—CHRM1—Signaling by GPCR—IL2RA—Graves' disease	1.58e-05	0.00055	CbGpPWpGaD
Doxepin—CHRM3—Signaling by GPCR—IL2RA—Graves' disease	1.58e-05	0.000548	CbGpPWpGaD
Doxepin—CHRM2—Signaling by GPCR—IL2RA—Graves' disease	1.56e-05	0.000543	CbGpPWpGaD
Doxepin—ADRA1A—Signaling by GPCR—IL2RA—Graves' disease	1.56e-05	0.000541	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—CXCL10—Graves' disease	1.47e-05	0.000512	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—IL2RA—Graves' disease	1.47e-05	0.000511	CbGpPWpGaD
Doxepin—ADRA2A—Signaling by GPCR—IL2RA—Graves' disease	1.45e-05	0.000503	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—CXCL10—Graves' disease	1.42e-05	0.000495	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—CXCL10—Graves' disease	1.42e-05	0.000492	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—GC—Graves' disease	1.4e-05	0.000488	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—IL2RA—Graves' disease	1.39e-05	0.000482	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—B3GNT2—Graves' disease	1.38e-05	0.000479	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—CXCL10—Graves' disease	1.38e-05	0.000479	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—CXCL10—Graves' disease	1.35e-05	0.000471	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—IL2RA—Graves' disease	1.34e-05	0.000466	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—IL2RA—Graves' disease	1.33e-05	0.000461	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—CXCL10—Graves' disease	1.25e-05	0.000434	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—IL2RA—Graves' disease	1.25e-05	0.000434	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—CXCL10—Graves' disease	1.23e-05	0.000427	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—CXCL10—Graves' disease	1.23e-05	0.000426	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—CXCL10—Graves' disease	1.22e-05	0.000425	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—CXCL10—Graves' disease	1.22e-05	0.000424	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—CXCL10—Graves' disease	1.21e-05	0.00042	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—CXCL10—Graves' disease	1.2e-05	0.000418	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—IL2RA—Graves' disease	1.13e-05	0.000392	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—CXCL10—Graves' disease	1.12e-05	0.000389	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—IL2RA—Graves' disease	1.09e-05	0.000378	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—IL2RA—Graves' disease	1.08e-05	0.000376	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—B3GNT2—Graves' disease	1.06e-05	0.00037	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—IL2RA—Graves' disease	1.05e-05	0.000366	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—IL2RA—Graves' disease	1.04e-05	0.00036	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—IL2RA—Graves' disease	9.55e-06	0.000332	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—IL2RA—Graves' disease	9.39e-06	0.000327	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—IL2RA—Graves' disease	9.37e-06	0.000326	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—IL2RA—Graves' disease	9.34e-06	0.000325	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—IL2RA—Graves' disease	9.31e-06	0.000324	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—IL2RA—Graves' disease	9.22e-06	0.000321	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—IL2RA—Graves' disease	9.2e-06	0.00032	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—IL2RA—Graves' disease	8.55e-06	0.000297	CbGpPWpGaD
